Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial
Weiya Z. Wysham*, Elisabeth M. Schaffer, Theresa Coles, Dario R. Roque, Stephanie B. Wheeler, Kenneth H. Kim
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial'. Together they form a unique fingerprint.